This trial is studying a new gene therapy called RGX-314 for wet age-related macular degeneration. Wet AMD is when new, leaky blood vessels form in the retina and cause vision loss. Current treatments require life-long intraocular injections, typically repeated every four to twelve weeks, to maintain efficacy. RGX-314 is being developed as a potential one-time treatment for wet AMD.
1 Primary · 6 Secondary · Reporting Duration: At Week 14, Week 26, Week 38, Week 54, and Week 98
Active Control
Experimental Treatment
300 Total Participants · 3 Treatment Groups
Primary Treatment: RGX-314 · No Placebo Group · Phase 2 & 3
Age 50 - 89 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:| Florida | 33.3% |
| Mississippi | 33.3% |
| Missouri | 33.3% |
| 65+ | 100.0% |
| Germantown Location | 100.0% |
| Did not meet criteria | 66.7% |
| Met criteria | 33.3% |
| 3+ | 100.0% |